Core Viewpoint - China Galaxy Securities reports that Innovent Biologics (01801) has become a leading biopharma company in China, excelling in innovative drug R&D, production, and commercialization, particularly in the oncology sector, which is expected to drive growth [1] Group 1: Financial Projections - The company is projected to achieve revenues of 11.891 billion, 14.836 billion, and 20.029 billion yuan for the years 2025, 2026, and 2027 respectively, with net profits of 0.824 billion, 1.378 billion, and 2.059 billion yuan for the same years [1] Group 2: Strategic Partnership with Takeda - On October 22, 2025, Innovent Biologics entered a global strategic partnership with Takeda Pharmaceutical to accelerate the global rollout of next-generation IO and ADC therapies, including IBI363, IBI343, and IBI3001, with an upfront payment of 1.2 billion USD and potential milestone payments totaling up to 11.4 billion USD [1] Group 3: Development of IBI363 - Innovent will co-develop IBI363 with Takeda, sharing development costs at a 40/60 ratio, and profits in the U.S. market will also be split 40/60, with Takeda leading the development [2] - IBI363 has shown promising data at the 2025 ASCO meeting, with a cORR of 36.7%, mPFS of 9.3 months, and a 12-month OS rate of 70.9%, with a global Phase III clinical plan set to launch soon [2] Group 4: Rights Granted for IBI343 and IBI3001 - Innovent has granted Takeda exclusive rights to IBI343 outside of Greater China, with potential milestone payments and high-tier sales sharing [3] - Takeda will focus on the global development of IBI343, particularly in first-line gastric and pancreatic cancer, while IBI3001's rights outside Greater China are also available for Takeda to exercise in the future [3]

Core Viewpoint - Xinda Biopharma has established itself as a leading player in China's biopharmaceutical sector, particularly in the oncology field, and is expected to continue its growth trajectory with new strategic partnerships and product developments [1] Group 1: Strategic Partnership - On October 22, 2025, Xinda Biopharma entered into a global strategic collaboration with Takeda Pharmaceutical to accelerate the global rollout of next-generation IO and ADC therapies, involving three products: IBI363, IBI343, and IBI3001 [1] - The collaboration includes an upfront payment of $1.2 billion (including a $100 million premium for strategic equity investment) and potential milestone payments, with a total deal value reaching up to $11.4 billion [1] Group 2: Product Development and Commercialization - Xinda will co-develop IBI363 with Takeda, sharing development costs at a 40/60 ratio and splitting profits from commercialization in the U.S. market similarly [2] - IBI363 has shown promising data at the 2025 ASCO conference, with a cORR of 36.7%, mPFS of 9.3 months, and a 12-month OS rate of 70.9% for immune-resistant NSCLC, with a global Phase III clinical plan set to launch soon [2] Group 3: ADC Product Rights - Xinda granted Takeda exclusive rights to IBI343 outside of Greater China, which includes potential milestone payments and high-tier percentage sales sharing [3] - IBI343 is currently undergoing Phase III clinical trials for gastric cancer in China and Japan, and has completed global Phase I/II trials for PDAC [3] - Additionally, Xinda has granted Takeda an option for early pipeline IBI3001 outside of Greater China, which could yield option fees, milestone payments, and high-tier sales sharing if exercised [3]

Group 1 - The core viewpoint of the articles highlights the strong performance of innovative drug stocks in the market, with notable increases in share prices for companies such as Gilead Sciences-B (up 8.82%) and Kintor Pharmaceutical (up 4.60%) [1] - The report from CICC emphasizes the importance of innovative drugs and medical devices in China's "14th Five-Year Plan," indicating a shift from "follow-up innovation" to "quality transformation" in domestic innovative drugs [1] - The collaboration between Hansoh Pharmaceutical and Roche for the global exclusive license of the antibody-drug conjugate HS-20110 is seen as a significant advancement, with expectations for smooth development due to Roche's expertise [2] Group 2 - The partnership between Innovent Biologics and Takeda Pharmaceutical aims to advance the development of next-generation tumor immunotherapy and antibody-drug conjugates, leveraging Takeda's strong sales network in Japan and the West [2] - Valiant Pharmaceuticals' agreement with the U.S. company Dianthus for the development and commercialization of its autoimmune drug LBL-047 outside Greater China is viewed as beneficial for product development [2] - The overall sentiment in the pharmaceutical industry is optimistic regarding the international expansion of innovative drugs, with multiple companies securing significant partnerships to enhance their research and commercialization efforts [2]

Group 1 - The Hang Seng Index rose by 0.56% to close at 27,073.03 points on November 13, with a total net sell of 3.52 billion HKD through the southbound trading channel [1] - The total trading amount for the southbound trading on November 13 was 124.97 billion HKD, with a net sell of 3.52 billion HKD [1] - The Shanghai Stock Exchange's southbound trading had a total trading amount of 75.99 billion HKD and a net sell of 2.13 billion HKD, while the Shenzhen Stock Exchange had a total trading amount of 48.98 billion HKD and a net sell of 1.39 billion HKD [1] Group 2 - In the top ten active stocks for the Shanghai Stock Exchange's southbound trading, Alibaba-W had the highest trading amount of 9.91 billion HKD, followed by the Tracker Fund of Hong Kong and SMIC with trading amounts of 4.27 billion HKD and 3.44 billion HKD respectively [2] - Alibaba-W had a net buy amount of 1.70 billion HKD, with its stock price increasing by 3.32% [2] - The Tracker Fund of Hong Kong had the highest net sell amount of 4.26 billion HKD, while its stock price increased by 0.52% [2] Group 3 - In the Shenzhen Stock Exchange's southbound trading, Alibaba-W also led with a trading amount of 5.99 billion HKD, followed by SMIC and Tencent Holdings with trading amounts of 2.61 billion HKD and 2.27 billion HKD respectively [2] - The highest net buy amount was for Huahong Semiconductor at 196 million HKD, with its stock price rising by 5.64% [2] - The highest net sell amount was again for the Tracker Fund of Hong Kong at 196 million HKD, with its stock price increasing by 0.52% [2]

Core Insights - Chinese innovative pharmaceutical companies are gaining global competitiveness, with different paths taken by companies like BeiGene and Innovent Biologics [1][4][5] - Innovent's approach is seen as more replicable compared to BeiGene's aggressive global strategy, which is viewed as a product of a specific window of opportunity [6][11] Company Strategies - Innovent Biologics has established a strong domestic foundation before expanding internationally, recently securing a $11.4 billion strategic partnership with Takeda Pharmaceuticals [3][4] - BeiGene, on the other hand, has pursued a global strategy from its inception, with significant investments in local talent and operations across various regions [5][9] Financial Performance - In the first three quarters of 2025, Innovent reported product revenues of approximately 8.63 billion yuan, while BeiGene's revenues were around 27 billion yuan [4][5] - Both companies have a significant number of products in various stages of development, with Innovent having 21 product lines and BeiGene over 40 [4][5] Market Challenges - Both companies face common challenges in market access, commercialization pricing, and intellectual property protection, which are evolving in the industry [11] - The traditional path for innovative drugs involves initial development in Western markets, followed by generic competition in developing countries, which can take over a decade [8][9] Future Outlook - Innovent aims to achieve 20 billion yuan in revenue within three years, focusing on a diversified product line, particularly in oncology [9] - The Chinese innovative drug sector is expected to play a more significant role globally in the next 5 to 10 years, with advantages in engineering talent and patient recruitment speed [10][11]

Core Viewpoint - The Hong Kong stock market experienced significant net selling from northbound capital, with a total net sell of 35.21 billion HKD on November 13, 2023, indicating a cautious sentiment among investors [1]. Group 1: Stock Performance - Alibaba-W (09988) saw a net inflow of 16.97 billion HKD, with a total trading volume of 99.09 billion HKD, reflecting strong investor interest [2]. - Xiaomi Group-W (01810) recorded a net inflow of 8.91 billion HKD, indicating positive market sentiment towards its stock [2]. - Tencent (00700) faced a net outflow of 8.68 billion HKD, highlighting investor concerns following its quarterly earnings report [2][6]. Group 2: Sector Trends - Semiconductor stocks, including Hua Hong Semiconductor (01347) and SMIC (00981), received net inflows of 868.1 million HKD and 760.6 million HKD respectively, driven by optimistic forecasts for the AI-driven semiconductor cycle extending until 2027 [5]. - The report from Morgan Stanley predicts global semiconductor revenue growth of 18% and 11% in 2026 and 2027, respectively, supporting the bullish outlook for Asian tech stocks [5]. Group 3: ETF Activity - The Hang Seng Index ETF (02800) and the Hang Seng China Enterprises Index ETF (02828) experienced significant net outflows of 62.26 billion HKD and 22.89 billion HKD, respectively, reflecting a broader market weakness [7]. - Despite the outflows, analysts maintain a cautiously optimistic view on the medium-term market outlook, emphasizing the importance of technology innovation and domestic demand [7].

Core Insights - On November 13, 2025, Alibaba-W (09988), the Tracker Fund of Hong Kong (02800), and SMIC (00981) were the top three stocks by trading volume in the Southbound Stock Connect, with trading amounts of 99.09 billion, 42.74 billion, and 34.39 billion respectively [1] - In the Shenzhen-Hong Kong Stock Connect, Alibaba-W (09988), SMIC (00981), and Tencent Holdings (00700) led the trading volume, with amounts of 59.89 billion, 26.06 billion, and 22.68 billion respectively [1] Southbound Stock Connect Top Active Companies - Alibaba-W (09988) had a trading amount of 99.09 billion with a net buying amount of +16.97 billion [2] - The Tracker Fund of Hong Kong (02800) recorded a trading amount of 42.74 billion with a net buying amount of -42.64 billion [2] - SMIC (00981) had a trading amount of 34.39 billion with a net buying amount of +4.71 billion [2] - Tencent Holdings (00700) had a trading amount of 31.35 billion with a net buying amount of -8.68 billion [2] - Xiaomi Group-W (01810) recorded a trading amount of 23.28 billion with a net buying amount of +8.91 billion [2] Shenzhen-Hong Kong Stock Connect Top Active Companies - Alibaba-W (09988) had a trading amount of 59.89 billion with a net buying amount of -3.23 billion [2] - SMIC (00981) recorded a trading amount of 26.06 billion with a net buying amount of -3.95 billion [2] - Tencent Holdings (00700) had a trading amount of 22.68 billion with a net buying amount of -679.98 million [2] - The Tracker Fund of Hong Kong (02800) recorded a trading amount of 19.73 billion with a net buying amount of -19.62 billion [2] - Xiaomi Group-W (01810) had a trading amount of 16.81 billion with a net buying amount of -1.11 billion [2]

Core Viewpoint - The Hong Kong innovative drug sector is experiencing strong performance, with significant stock price increases for several companies in the industry [1] Company Performance - Sanofi Pharmaceutical (01530.HK) increased by 10.11%, reaching HKD 33.76 [1] - Innovent Biologics (02096.HK) rose by 7.52%, trading at HKD 14.02 [1] - BeiGene (06160.HK) saw a 7.34% increase, with shares priced at HKD 228.2 [1] - China Biologic Products (01177.HK) gained 6.79%, now at HKD 7.39 [1] - I-Mab (01801.HK) experienced a 6.37% rise, with shares at HKD 92.7 [1]

Group 1 - The innovative drug sector has shown strong performance, with notable stock increases for companies such as Sangamo Therapeutics (up 10.11%), Innovent Biologics (up 7.52%), BeiGene (up 7.34%), China Biologic Products (up 6.79%), and I-Mab (up 6.37%) [1] - In Q3, the innovative drug sector reported a revenue growth of 1.98% year-on-year and a net profit attributable to the parent company increased by 7.25% year-on-year [1] - Despite adjustments since September, the overall trend for the innovative drug industry remains positive, supported by domestic policy and the Federal Reserve entering a rate-cutting cycle, with a significant number of licensing deals expected in the next six months to a year [1] Group 2 - Guotai Junan Securities noted that the innovative drug sector continued to experience high revenue growth and profitability turnaround in Q3, indicating a long-term positive development trend for China's innovative drug industry [2] - The explosive growth in business development (BD) transactions has been a key highlight in recent years for the domestic innovative drug sector [2] - For most domestic innovative drugs, external licensing is often just the starting point for global development, with the progress of partners in overseas development and subsequent global clinical data readings enhancing the commercial certainty of products in the global market [2]

Group 1 - The innovative drug sector shows strong performance, with notable stock price increases for companies such as 三生制药 (up 10.11%), 先声药业 (up 7.52%), and 百济神州 (up 7.34%) [1] - In Q3, the innovative drug sector's revenue grew by 1.98% year-on-year, while net profit attributable to shareholders increased by 7.25% year-on-year [1] - Despite adjustments since September, the overall trend for the innovative drug industry remains positive, supported by domestic policies and the Federal Reserve entering a rate-cutting cycle [1] Group 2 - The innovative drug sector continued to experience high revenue growth and profitability turnaround in Q3, indicating a long-term positive development trend [2] - The surge in business development (BD) transactions highlights the growth potential of the Chinese innovative drug industry [2] - For most domestic innovative drugs, external licensing is often just the starting point for global development, with subsequent clinical data enhancing commercial certainty in global markets [2]